Bimekizumab Efficacy & Safety Versus Risankizumab in Patients with Active Psoriatic Arthritis: 24-Week Results from a Head-To-Head, Multicenter, Randomized, Phase 3b Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2804; Pres time: Nov 10, 2026; 10:15 AM - 10:30 AM; Location: Chapin Theater; In Person; P3 | "Dual inhibition of IL-17A/F with BKZ was superior to RZB for ACR50 at Wk16. Additional exploratory analysis demonstrated that a greater proportion of patients receiving BKZ achieved ACR50 at each timepoint from Wk4 to Wk24, compared to RZB. No new safety signals were identified."
Clinical • Head-to-Head • P3 data • Candidiasis • Immunology • Infectious Disease • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A • IL23A
|
|
Iain McInnes1; Laure Gossec2; Alice Gottlieb3; Philip Mease4; Akimichi Morita5; Yoshiya Tanaka6; Diamant Thaçi7; Barbara Ink8; Alexander Marten9; Jason Coarse10; Adam Prickett8; Nadine Goldammer9; Myriam Manente11; Joseph Merola12
|